Patents by Inventor Thomas E. Ichim

Thomas E. Ichim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250115867
    Abstract: Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.
    Type: Application
    Filed: December 16, 2024
    Publication date: April 10, 2025
    Inventors: Stephen D. WOLPE, Leonard MILLER, Lynnet KOH, Thomas E. ICHIM
  • Publication number: 20240377385
    Abstract: Disclosed herein are methods and compositions for treating cancer. Further disclosed herein are methods and compositions useful for predicting the response of a patient bearing a tumor to therapy of such tumor.
    Type: Application
    Filed: May 10, 2024
    Publication date: November 14, 2024
    Inventors: Thomas E. Ichim, Gregory DiRienzo, Yi Ma, Nicole DiRienzo
  • Publication number: 20240307446
    Abstract: B cell subsets, generation of B cell subsets and utilization of B cell subsets for treatment of Chronic Obstructive Pulmonary Disease (COPD). In one embodiment B cells possessing a B regulatory phenotype are generated in vivo by administrating of mesenchymal stem cells. In another embodiment B regulatory cells are utilized to treat COPD in an interleukin-35 dependent manner. In another embodiment B regulatory cells possess the marker CD5 and produce interleukin-10.
    Type: Application
    Filed: March 14, 2024
    Publication date: September 19, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: THOMAS E. ICHIM, TIMOTHY G. DIXON, JAMES VELTMEYER
  • Publication number: 20240269148
    Abstract: Parallels between pregnancy and cancer have been historically made, however, the ability to leverage abortogenic immunity against neoplasia has not been widely examined. The current invention provides means of suppressing tumor associated immune inhibition through administration of progesterone and/or glucocorticoid receptor antagonists such as RU-486. In one embodiment the invention provides the concurrent utilization RI-486 and anti-angiogenic immunotherapy. In another embodiment, abortogenic inhibitors of immunity such as indolamine 2,3 dioxygenase are administered together with RU-486 and/or anti-angiogenic immunotherapy. Various antiangiogenic agents can be utilized in the practice of the invention including the ValloVax immunotherapy and/or the StemVacs-V therapy.
    Type: Application
    Filed: February 15, 2024
    Publication date: August 15, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon
  • Publication number: 20240271093
    Abstract: Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.
    Type: Application
    Filed: April 8, 2024
    Publication date: August 15, 2024
    Inventors: Stephen D. Wolpe, Leonard Miller, Lynnet Koh, Thomas E. Ichim
  • Publication number: 20240241119
    Abstract: Disclosed are novel means of stratifying patients into potential of positive response to mesenchymal stem cell therapy based on quantification of pretreatment levels of B regulatory cells. In one embodiment quantification of cells concurrently expressing CD5 and CD19. In another embodiment B regulatory cells are CD19+CD39?IL10+. In one embodiment the selection of B regulatory cells is quantified by flow cytometric means and patients possessing more than 7% IL-10 secreting CD19 cells are chosen for stem cell therapy. In some embodiments numbers of B regulatory cells are increased prior to treatment by administration of various interventions including providing GM-CSF, microbiome alteration or manipulation of oxidative stress.
    Type: Application
    Filed: January 11, 2024
    Publication date: July 18, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, James VELTMEYER, Timothy G. DIXON
  • Publication number: 20240226172
    Abstract: Disclosed are novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes.
    Type: Application
    Filed: October 24, 2023
    Publication date: July 11, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, James VELTMEYER
  • Publication number: 20240216472
    Abstract: Disclosed are means, methods, and compositions of matter useful for induction of antigen specific suppression of immunity and/or tolerogenesis through administration of tolerogenic agents together with antigens and/or modified antigens delivered via multiple intradermal injections. In one embodiment the invention teaches the use of a tattoo gun or a similar device to administer over an extended area of skin a compound which induces a tolerogenic microenvironment and subsequently administration of said antigen in the artificially created microenvironment.
    Type: Application
    Filed: January 4, 2024
    Publication date: July 4, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Kalina O'CONNOR, James VELTMEYER, Timothy G. DIXON
  • Publication number: 20240207309
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In 5 one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Application
    Filed: January 23, 2024
    Publication date: June 27, 2024
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Patent number: 12011462
    Abstract: Disclosed are novel means of enhancing mesenchymal stem cell regenerative activities including, intra alia, production from pulmonary leakage and suppression of scar tissue formation by co-administration with T regulatory cells. In some embodiments the invention provides an interaction between T regulatory cells and mesenchymal stem cells in which T regulatory cells stimulate upregulation of mesenchymal stem cell activity in a GITR dependent manner.
    Type: Grant
    Filed: September 22, 2022
    Date of Patent: June 18, 2024
    Assignee: Therapeutic Solutions International, Inc
    Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon, Feng Lin, Kalina O'Connor
  • Publication number: 20240156862
    Abstract: Disclosed are compositions of matter, protocols, and treatment means for prevention and/or reversing Chronic Obstructive Pulmonary Disease (COPD) using myeloid derived suppressor cells as a monotherapy or adjuvant therapy. In one embodiment umbilical cord low density myeloid cells are expanded using interleukin-3 and GM-CSF and administered in an allogeneic manner to a mammal suffering from COPD. In some embodiments combinations of myeloid derived suppressor cells and mesenchymal stem cells are disclosed.
    Type: Application
    Filed: November 14, 2023
    Publication date: May 16, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, James VELTMEYER
  • Patent number: 11976298
    Abstract: Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: May 7, 2024
    Assignee: Targazyme, Inc.
    Inventors: Stephen D. Wolpe, Leonard Miller, Lynnet Koh, Thomas E. Ichim
  • Publication number: 20240131076
    Abstract: Disclosed are novel compositions of matter and treatment methods for reducing and/or reversing epilepsy through administration of mesenchymal stem cells in order to induce immune modulation and/or regenerative processes.
    Type: Application
    Filed: October 23, 2023
    Publication date: April 25, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, James VELTMEYER
  • Patent number: 11957727
    Abstract: Disclosed are means, methods, and therapeutic compositions for prevention of memory loss during situations of neuroinflammation. In one embodiment the invention teaches administration of the therapeutic combination of ingredients comprising of pterostilbene, Nigella sativa, sulforaphane, and epigallocatechin-3-gallate (EGCG) to a mammal suffering from inflammation in order to preserver memory function.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: April 16, 2024
    Assignee: Therapeutic Solutions International, Inc
    Inventors: Thomas E. Ichim, Famela Ramos, James Veltmeyer, Timothy G. Dixon
  • Publication number: 20240091269
    Abstract: The invention discloses the utilization of mesenchymal stem cells, exosomes from mesenchymal stem cells, conditioned media from mesenchymal stem cells, apoptotic bodies from mesenchymal stem cells, and modified mesenchymal stem cells for treatment of bipolar disorder. In one embodiment mesenchymal stem cells isolated from umbilical cord tissue are treated carbon monoxide at a concentration sufficient to induce activation of heme-oxygenase I and infused into a patient at risk or suffering from bipolar disorder.
    Type: Application
    Filed: September 19, 2023
    Publication date: March 21, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, James VELTMEYER, Kalina O'CONNOR
  • Publication number: 20240082356
    Abstract: Disclosed are means of inducing pulmonary regeneration and/or protection from oxidative stress by stimulation of endogenous stem cell mobilization together with one or more inhibitors of NF-kappa B and/or one or more inhibitors of oxidative stress. The invention discloses the unexpected finding that G-CSF administration enhances oxidative stress and pulmonary damage, however, coadministration with pterostilbene, results in synergistic suppression of COPD pathology.
    Type: Application
    Filed: September 12, 2023
    Publication date: March 14, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, James VELTMEYER
  • Publication number: 20240076679
    Abstract: Disclosed are treatment means, compositions of matter and protocols useful for suppression of acute respiratory disorder (ARDS) through induction of RNA interference in the pulmonary microenvironment alone and/or in conjunction with mucolytic and/or DNA disrupting agents. In one embodiment short interfering RNA (siRNA) is prepared which targets complement receptors C3R and/or C5R together with TNF-receptor, IL-6 receptor and/or TLR4 and TLR9. In some embodiments nanostilbene is utilized as a delivery vehicle for siRNA delivery.
    Type: Application
    Filed: August 29, 2023
    Publication date: March 7, 2024
    Applicant: Therapeutic Solutions International, Inc.
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, James VELTMEYER
  • Patent number: 11918605
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: March 5, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Patent number: 11918604
    Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: March 5, 2024
    Assignee: MYELOID THERAPEUTICS, INC.
    Inventors: Samuel C. Wagner, Thomas E. Ichim, Julia S. Szymanski, Santosh Kesari, Amit N. Patel, Boris Minev
  • Publication number: 20240050485
    Abstract: Disclosed are means, treatments and compositions of matter useful for treatment of chronic obstructive pulmonary disease (COPD). In one embodiment the invention provides the administration of mesenchymal stem cell apoptotic bodies alone or in combination with “regenerative adjuvants” to prevent and/or reverse reduction in lung function associated with COPD. In other embodiments the invention teaches the utilization of stem cell apoptotic bodies for induction of pulmonary regeneration directly or indirectly.
    Type: Application
    Filed: August 14, 2023
    Publication date: February 15, 2024
    Inventors: Thomas E. ICHIM, Timothy G. DIXON, Feng LIN, James VELTMEYER